Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial

Area of Science:

• Nephrology
• Ophthalmology
• Endocrinology

Background:

• Diabetic retinopathy and nephropathy share microangiopathy as a characteristic feature.
• The optimal use of angiotensin-converting enzyme (ACE) inhibitors in diabetic patients remains unclear.
• Type I diabetes with early nephropathy presents a specific cohort for investigating ACE inhibitor efficacy.

Purpose of the Study:

• To evaluate the efficacy of captopril, an ACE inhibitor, in treating diabetic retinopathy in patients with Type I diabetes and early nephropathy.
• To assess the impact of captopril on both retinal and renal microvascular complications.
• To determine if ACE inhibitors offer a therapeutic benefit in this specific diabetic population.

Main Methods:

• A double-blind, placebo-controlled study was conducted.
• Participants had Type I diabetes, early diabetic nephropathy (20-200 micrograms/min albumin excretion), and normal blood pressure.
• Captopril was administered to the treatment group, with a placebo group serving as a control over two years.

Main Results:

• Two captopril-treated subjects showed improved eye grades, while no control subjects did.
• Three control subjects and one treated subject experienced worsening eye grades (P < .001).
• No significant differences in renal albumin excretion were observed between the groups, but retinal grade changes favored the treatment group.

Conclusions:

• Captopril demonstrated a potential benefit in improving diabetic retinopathy in the studied cohort.
• The study suggests a possible role for ACE inhibitors in managing diabetic retinopathy, though not definitively for nephropathy in this group.
• Larger trials are required to confirm these findings and identify patient subgroups most likely to benefit from ACE inhibitor therapy.